Expertise

robert blank_headshotbw

Robert Blank

Managing Consultant

EVERSANA

Robert Blank

Robert Blank is a managing consultant at EVERSANA, working extensively in revenue management software solutions for the pharmaceutical and medical device industries. His expertise includes Medicaid and Managed Care rebates, chargebacks, and membership management. He has developed custom client solutions around value based contracting, formulary validation, discount reallocation, and the 340B Drug Pricing Program. In his speaking engagements and published articles, Robert focuses on outlining industry trends and the impacts of legislation upon commercial operations.

Expertise:

Revenue Management

Articles by Robert Blank

Evolving Processes to Manage Value-Based Contracts

For the past several years, the pharmaceutical industry has focused on exploring and establishing value-based contracts (VBCs) between manufacturers and their customers. In these arrangements, payments are predicated upon measurements of patient welfare, rather than formulary access, purchase volumes or market share. Yet, despite the appeal of these arrangements, many manufacturers have been reticent to […]

More Data, More Problems, More Potential

As the healthcare industry shifts from volume-based care to a value-based reimbursement structure, data analytics will be critical in shaping the future of the pharmaceutical industry. More so than perhaps any recent industry trend, value base contracting is positioned at a unique intersection between various disciplines in the pharmaceutical industry. Clinical data informs market research, […]

Challenges and Best Practices in Managing Value Based Contracts

Manufacturers face a variety of hurdles when negotiating value based contracts: from data access and standardization, deal structure variation, payment variability and scheduling, to changing laws and regulations. And, as the industry shifts to value-driven healthcare, the demand for innovative product commercialization and pricing models grows. In this webinar EVERSANA experts Robert Blank and Mike […]

white paper-insights
Gross-to-Net Improvement Through Holistic Revenue Enhancement

Consistent price increases have long been a staple of commercial strategy for pharmaceutical manufacturers. From this uplift in topline revenue, more sizable discounts can be provided to industry middlemen, like pharmacy benefit managers (PBMs), in order to secure more favorable formulary positioning. Rather than continue forward with traditional market access strategies, manufacturers should consider revenue […]

white paper-insights
340B Drug Pricing: Challenges and Best Practices

Enacted in 1992, the 340B Drug Pricing Program was intended to stretch scarce federal resources and services to more eligible patients. Despite achieving this goal in many respects, it hasĀ  also become notoriously difficult to manage for the more than 600 pharmaceutical companies enrolled. Data validity, crossover between lines of business, and conflicting regulations each […]

Interested in scheduling a meeting or speaking event?

Contact Us

  • This field is for validation purposes and should be left unchanged.